North Star Investment Management Corp. lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) by 16.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 367,300 shares of the biotechnology company’s stock after selling 74,600 shares during the period. North Star Investment Management Corp. owned 0.20% of BioCryst Pharmaceuticals worth $4,217,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in BCRX. Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals by 40.3% in the first quarter. Vanguard Group Inc. now owns 13,207,040 shares of the biotechnology company’s stock worth $214,746,000 after buying an additional 3,794,135 shares during the last quarter. State Street Corp grew its holdings in BioCryst Pharmaceuticals by 47.5% during the second quarter. State Street Corp now owns 11,004,803 shares of the biotechnology company’s stock valued at $116,431,000 after purchasing an additional 3,542,051 shares during the last quarter. Millennium Management LLC grew its holdings in BioCryst Pharmaceuticals by 3,445.8% during the second quarter. Millennium Management LLC now owns 1,948,595 shares of the biotechnology company’s stock valued at $20,616,000 after purchasing an additional 1,893,640 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in BioCryst Pharmaceuticals by 64.0% during the first quarter. Loomis Sayles & Co. L P now owns 2,356,216 shares of the biotechnology company’s stock valued at $38,312,000 after purchasing an additional 919,104 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in BioCryst Pharmaceuticals by 325.1% during the third quarter. Two Sigma Investments LP now owns 1,031,159 shares of the biotechnology company’s stock valued at $12,993,000 after purchasing an additional 788,618 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have commented on BCRX. Royal Bank of Canada reiterated a “sector perform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, March 14th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 22nd. Barclays reduced their price objective on BioCryst Pharmaceuticals from $12.00 to $10.00 in a research report on Friday, December 16th. StockNews.com started coverage on BioCryst Pharmaceuticals in a research report on Thursday. They issued a “hold” rating for the company. Finally, Needham & Company LLC raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, February 22nd. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.78.
Insider Buying and Selling
BioCryst Pharmaceuticals Price Performance
Shares of BCRX stock opened at $8.10 on Friday. The stock has a market cap of $1.53 billion, a P/E ratio of -6.09 and a beta of 2.03. BioCryst Pharmaceuticals, Inc. has a one year low of $7.61 and a one year high of $18.00. The stock has a fifty day moving average price of $9.75 and a 200 day moving average price of $11.61.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) last issued its earnings results on Tuesday, February 21st. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.19). The company had revenue of $79.50 million during the quarter, compared to analysts’ expectations of $74.18 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 68.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.40) earnings per share. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.98 EPS for the current year.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.
- Get a free copy of the StockNews.com research report on BioCryst Pharmaceuticals (BCRX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.